John A. Heit, MD; C. Gregory Elliott, MD; Arthur A. Trowbridge, MD; Bernard F. Morrey, MD; Michael Gent, DSc; Jack Hirsh, MD; for the Ardeparin Arthroplasty Study Group*
Acknowledgments: The authors thank the surgical, nursing, pharmacy, and support staff at all the study sites. They also thank Dr. D. Scott Holloway and Ms. Joanne DiLiberto, Wyeth-Ayerst Research.
Grant Support: By Wyeth-Ayerst Research, Philadelphia, Pennsylvania.
Requests for Single Reprints: John A. Heit, MD, Hematology Research, Plummer 549, Mayo Clinic, 200 First Street SW, Rochester, MN 55905.
Requests To Purchase Bulk Reprints (minimum, 100 copies): the Reprints Coordinator; phone, 215-351-2657; e-mail, firstname.lastname@example.org.
Current Author Addresses: Dr. Heit: Hematology Research, Plummer 549, Mayo Clinic, 200 First Street SW, Rochester, MN 55905.
Dr. Elliott: LDS Hospital, University of Utah, Eighth Avenue and C Street, Salt Lake City, UT 84143.
Dr. Trowbridge: Texas A&M University, 2401 South 31st Street, Temple, TX 76508.
Dr. Morrey: Mayo Clinic, 200 First Street, SW, Rochester, MN 55905.
Drs. Gent and Hirsh: Hamilton Civic Hospitals Research Centre, 711 Concession Street, Hamilton, Ontario L8V 1C3, Canada.
Author Contributions: Conception and design: C.G. Elliott, B.F. Morrey, J.A. Heit, J. Hirsh.
Analysis and interpretation of the data: C.G. Elliott, A.A. Trowbridge, M. Gent, J.A. Heit, J. Hirsh.
Drafting of the article: A.A. Trowbridge, M. Gent, J.A. Heit, J. Hirsh.
Critical revision of the article for important intellectual content: C.G. Elliott, A.A. Trowbridge, M. Gent, J.A. Heit, J. Hirsh.
Final approval of the article: C.G. Elliott, A.A. Trowbridge, B.F. Morrey, J.A. Heit, J. Hirsh.
Provision of study materials or patients: C.G. Elliott, A.A. Trowbridge, J.A. Heit, B.F. Morrey.
Statistical expertise: M. Gent.
Administrative, technical, or logistic support: M. Gent.
Collection and assembly of data: C.G. Elliott, J.A. Heit.
The optimal duration of prophylaxis against venous thromboembolism after total hip or knee replacement is uncertain.
To determine the efficacy and safety of extended out-of-hospital prophylaxis with low-molecular-weight heparin (ardeparin sodium).
Randomized, double-blind, placebo-controlled trial.
33 community, university, or university-affiliated hospitals.
1195 adults who had elective total hip or knee replacement and completed 4 to 10 days of postoperative ardeparin prophylaxis.
Daily subcutaneous ardeparin (100 IU/kg of body weight) or placebo from time of hospital discharge to 6 weeks after surgery.
Symptomatic, objectively documented venous thromboembolism or death, along with major bleeding, from time of hospital discharge to 12 weeks after surgery.
Patients who received ardeparin (n = 607) and those who received placebo (n = 588) did not differ significantly in the cumulative incidence of venous thromboembolism or death (9 cases [1.5%] compared with 12 cases [2.0%]; odds ratio, 0.7 [95% CI, 0.3 to 1.7]; P > 0.2; absolute difference, −0.56 percentage points [CI, −2.2 to 1.1 percentage points]) or major bleeding (2 cases [0.3%] compared with 3 cases [0.5%]).
Among patients who had total knee or total hip replacement and received 4 to 10 days of postoperative ardeparin prophylaxis, the cumulative incidence of symptomatic venous thromboembolism or death after hospital discharge was not significantly reduced by extended out-of-hospital ardeparin prophylaxis. Extended ardeparin use could provide a maximum 2.2–percentage point true reduction in such events. The benefit of extended ardeparin use is not clinically important for most patients. Future research should identify high-risk patients who would benefit most from extended prophylaxis.
*For members of the Ardeparin Arthroplasty Study Group, see Appendix.
Learn more about subscription options.
Register Now for a free account.
Heit JA, Elliott CG, Trowbridge AA, Morrey BF, Gent M, Hirsh J, et al. Ardeparin Sodium for Extended Out-of-Hospital Prophylaxis against Venous Thromboembolism after Total Hip or Knee Replacement: A Randomized, Double-Blind, Placebo-Controlled Trial. Ann Intern Med. 2000;132:853–861. doi: 10.7326/0003-4819-132-11-200006060-00002
Download citation file:
Published: Ann Intern Med. 2000;132(11):853-861.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only